# Sight Sciences, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/Sight Sciences, Inc.).

## Overview

Sight Sciences, Inc. develops and commercializes interventional ophthalmic technologies used by eye care providers to treat glaucoma and dry eye disease. Its portfolio includes surgical devices for glaucoma procedures and the TearCare system for dry eye treatment, sold primarily in the United States with additional international distribution in select European markets.

## Products & services

• OMNI surgical system for glaucoma procedures
• SION device for glaucoma treatment
• TearCare system for dry eye disease
• TearCare SmartHubs and SmartLids consumables
• Clinical education and training for eye care providers

- **Surgical Glaucoma** (98%) — Interventional devices used by ophthalmic surgeons in glaucoma procedures, including OMNI and SION.
- **Dry Eye** (2%) — TearCare systems, SmartHubs, SmartLids, and related accessories for dry eye treatment.

- OMNI surgical system for glaucoma procedures
- SION device for interventional glaucoma treatment
- TearCare system for dry eye disease
- TearCare SmartHubs and SmartLids consumables
- Clinical education and training for eye care providers

## Customers

Sight Sciences sells primarily to eye care providers, including ophthalmologists, optometrists, ambulatory surgery centers, and hospital outpatient departments. Its glaucoma products are used in procedural settings, while TearCare is purchased by practices that treat dry eye patients and reorder consumables over time.

- **Ambulatory surgery centers and HOPDs** (primary) — Buy OMNI and SION for outpatient glaucoma procedures and value devices that fit procedural workflows.
- **Ophthalmology practices** (primary) — Purchase glaucoma devices and TearCare systems to expand treatment options for eye disease patients.
- **Optometry practices** (secondary) — Buy TearCare for dry eye treatment and recurring SmartLid consumables.
- **Third-party payors** (primary) — Influence adoption through reimbursement and coverage decisions for TearCare and related procedures.

- Ophthalmic surgeons performing glaucoma procedures
- Ambulatory surgery centers and hospital outpatient departments
- Optometry and ophthalmology practices treating dry eye
- Practice administrators and ECPs evaluating reimbursement and workflow
- Payors indirectly influence adoption through coverage decisions

## Geography

The company generates substantially all of its revenue in the United States, where its direct sales organization is concentrated. It also sells OMNI in select European countries through distributors and maintains direct sales in Germany and the United Kingdom, making reimbursement and market access important in both U.S. and European markets.

- **United States** (95%) — Substantially all revenue is generated in the U.S. based on MD&A disclosure.
- **Europe** (5%) — Select European countries, with direct sales in Germany and the UK.

- Substantially all revenue is generated in the United States
- Direct sales force is concentrated in the U.S. market
- OMNI is sold through distributors in select European countries
- Direct sales are maintained in Germany and the United Kingdom
- European reimbursement and market access affect adoption

## Strategy

Sight Sciences is focused on expanding adoption of its interventional eye care technologies by building clinical evidence, improving reimbursement access, and increasing provider awareness. It is also investing in commercial coverage, education, and international expansion while continuing to develop new products for glaucoma and ocular surface disease.

- **Expand reimbursement for TearCare** (short-term) — Coverage decisions are central to patient access and adoption in dry eye.
- **Strengthen commercial execution** (short-term) — The products require specialized training and consultative selling to drive procedural adoption.
- **Broaden international markets** (medium-term) — Geographic expansion can diversify revenue and extend the installed base.
- **Develop new interventional technologies** (long-term) — Pipeline innovation supports long-term relevance in glaucoma and ocular surface disease.

- Build clinical and health economic evidence for TearCare
- Expand reimbursement and market access for dry eye treatment
- Increase commercial coverage and provider awareness
- Grow adoption of OMNI standalone procedures
- Expand into additional international markets

## Risks

The business depends on reimbursement, physician adoption, and continued clinical differentiation in highly competitive ophthalmic markets. It also relies on third-party manufacturing, including significant sourcing from China and single-source suppliers, which creates supply chain, tariff, and quality risks.

- **Reimbursement and coverage risk** [high] — TearCare adoption depends on payor coverage and coding status.
- **Competitive pressure in MIGS and dry eye** [high] — Larger and better-capitalized rivals can offer alternative devices and procedures.
- **Third-party manufacturing and supply chain concentration** [high] — The company relies on external manufacturers and many components are single-source.
- **China sourcing and tariff exposure** [medium] — A substantial portion of products and components are manufactured in China.
- **Early-stage operating losses** [high] — The company expects continued losses while investing in commercialization and product development.

- Reimbursement changes can slow TearCare adoption
- Competition may pressure pricing and customer trialing
- Single-source manufacturing increases supply disruption risk
- China sourcing exposes the company to tariffs and import risk
- Clinical adoption depends on provider training and evidence

## Accounting

Key accounting judgments include revenue recognition for device sales and recurring consumables, which can be affected by shipment timing and reorder patterns. Investors should also watch estimates tied to stock-based compensation, debt-related costs, and any impairment or valuation judgments as the company continues to invest and finance growth.

- **Revenue recognition** — Affects quarterly revenue mix and comparability
- **Stock-based compensation** — Affects operating expense and net loss
- **Debt-related accounting** — Affects interest expense and below-operating items
- **Seasonality** — Affects quarterly revenue and margin comparability

- Revenue timing can vary with device shipments and consumable reorders
- Dry Eye sales are sensitive to quarterly demand and reimbursement changes
- Stock-based compensation affects operating expense and reported losses
- Debt issuance and extinguishment costs can affect non-operating results
- Emerging growth company status may affect accounting standard timing

---

*Last updated: 2026-04-29T04:58:30.490394+00:00*